Ampli®cation of genes in the 12q13-15 region occurs frequently in several malignancies including osteosarcoma. The products of these ampli®ed genes are thought to provide cancer cells with a selective growth advantage; however, the speci®c gene(s) driving this amplicon is unknown. We have previously shown that the SAS gene is ampli®ed in most parosteal osteosarcomas. In this study we analysed additional putative growth regulatory genes in this chromosomal region in 24 primary osteosarcoma specimens. CDK4 and SAS were coampli®ed in 6/6 parosteal tumors, and MDM2 was also ampli®ed in 4/5 parosteal cases. In comparison, ampli®cation occurred in only 2/16 classical intramedullary osteosarcomas and involved the SAS gene. Each ampli®ed gene had a correspondingly elevated mRNA level. Four high grade intramedullary tumors had elevated mRNA expression of SAS, but did not exhibit gene ampli®cation. Gene ampli®cation/overexpression was not associated with metastatic disease and did not change markedly with tumor progression, as evidenced by analysis of sequential tumor specimens from eight patients. Three other genes in the 12q13-15 region (CDK2, WNT1 and WNT10b) were not ampli®ed in any of the tumors. The dierent patterns of gene ampli®ca-tion and overexpression of CDK4, SAS and MDM2 in parosteal and intramedullary osteosarcomas may help explain the disparity in the biological behaviour of these two types of osteosarcoma.
Introduction
The long arm of human chromosome 12 contains a region that has been found to be ampli®ed in a number of dierent tumors, including osteosarcomas (OSA) and soft tissue sarcomas. Gene ampli®cation is one mechanism by which tumor cells can overexpress a gene product and gain a growth advantage. Identification of the speci®c gene on 12q13-15 that has been selected for is complicated by the fact that multiple genes are co-ampli®ed as part of the ampli®cation unit (Berner et al., 1996; Fischer et al., 1996; Reifenberger et al., 1996) . However, not all candidates are consistently ampli®ed and overexpressed in tumor samples. The SAS (sarcoma ampli®ed sequence; Meltzer et al., 1991; Jankowski et al., 1994) gene is located in this region, as well as a number of other genes including MDM2 (a p53 associated protein; Oliner et al., 1992; Leach et al., 1993) and CDK4 cyclin dependent kinase (Matsushime et al., 1994; Khatib et al., 1993) . Recently, CDK2 cyclin dependent kinase, WNT1 and WNT10b have also been mapped to this chromosomal region, although their amplification status in tumors has not been thoroughly examined (Arheden et al., 1988; Demetrick et al., 1994; Bui et al., 1997) .
Any of the above genes would be likely candidates driving 12q13-15 ampli®cation. MDM2 is transcriptionally activated by p53 (Barak et al., 1993) and also binds and inactivates the p53 protein (Momand et al., 1992) . This leads to down-regulation of p21 which normally binds cyclin/cdk complexes and thereby blocks DNA replication and cell cycle progression (El-Deiry et al., 1993; Li et al., 1994) . In this way, alterations of MDM2 can impact on both the p53 and pRb growth control mechanisms. As a result, it is not surprising that MDM2 is tumorigenic when overexpressed (Fakharzadeh et al., 1991; DubsPoterszman et al., 1995; Lundgren et al., 1997) and may be selected for by the 12q13-15 amplicon. In fact, it has been suggested that ampli®cation and overexpression of MDM2 may have a similar eect to p53 mutations, which are known to occur in approximately 25% of high grade OSA (Toguchida et al., 1992; Leach et al., 1993; Reifenberger et al., 1993; Cordon-Cardo et al., 1994; Mousses et al., 1996; Lonardo et al., 1997) .
CDK4 is involved in phosphorylation and inactivation of the retinoblastoma tumor suppressor protein (pRb), which leads to cell cycle progression (Ewen et al., 1993a; Kato et al., 1993; Matsushime et al., 1994) . Therefore overexpression of CDK4 alone may result in loss of cell cycle control by normal regulatory signals, resulting in unchecked cellular proliferation. Overexpression of CDK4 has been shown to rescue ®broblasts from p53-mediated growth arrest (Latham et al., 1996) , as well as lung epithelial cells from TGF-b inhibition (Ewen et al., 1993b) .
SAS encodes a transmembrane four superfamily (TM4SF) protein whose members are considered to play a role in signal transduction and growth control (Jankowski et al., 1994) . SAS has been shown to be ampli®ed in some types of bone and soft tissue sarcomas (Smith et al., 1992; Forus et al., 1993; Khatib et al., 1993; . The function of the SAS gene is presently unknown, and the biological signi®cance of SAS gene ampli®cation remains uncertain.
Analysis of tumors has identi®ed CDK4, SAS and MDM2 as being the most consistently ampli®ed and overexpressed of the genes in the 12q13-15 amplicon, but has not proven which may be most critical (Reifenberger et al., 1994; Nilbert et al., 1995; Berner et al., 1996) . In addition, recent studies have indicated that this amplicon may consist of 2 or more discontinuous regions, one containing MDM2 and another containing CDK4 and SAS (Nilbert et al., 1995; Berner et al., 1996; Reifenberger et al., 1996; Wolf et al., 1997) . This raises the possibility that MDM2 and CDK4/SAS are separate targets of ampli®cation.
We have previously shown that a speci®c type of osteosarcoma (OSA), parosteal/surface OSA, exhibits SAS gene ampli®cation signi®cantly more often than classical intramedullary tumors which constitute the majority of OSA . OSA are mesenchymal tumors in which the malignant cells directly produce osteoid or immature bone. Classical OSA are high grade malignancies which usually arise within the intramedullary canal of a long bone. Histologically these tumors are characterized by a cellular spindle cell stroma, cytologically abnormal cells producing osteoid and multiple abnormal mitotic ®gures. These tumors have a guarded prognosis despite treatment with aggressive chemotherapy and surgery (Souhami et al., 1997) . In contrast, a minority of OSA occur predominantly on the surface of the bone (parosteal OSA) and tend to be of lower histologic grade. They are also composed of spindle cells but the stroma is paucicellular, there is minimal cytologic atypia and mitoses are rare. Parosteal tumors exhibit a more dierentiated phenotype in that they produce abundant well formed bony trabeculae, have little risk of metastasis and a high cure rate with surgery alone (Unni et al., 1976; Raymond, 1991) . Identifying genetic dierences between these two tumor types is important to advance our understanding of the biological spectrum of osteosarcoma, and may provide new prognostic and disease-speci®c markers.
In this report we examined the possible role of DNA ampli®cation of CDK4, MDM2, and three other genes recently localized to 12q13-15 (CDK2, WNT1 and WNT10b) in both types of OSA. We also evaluated the levels of mRNA expression of SAS, CDK4 and MDM2 to evaluate the involvement of each of these genes in neoplastic growth of parosteal and classical intramedullary OSA.
Results

Co-ampli®cation of CDK4, SAS and MDM2 in surface osteosarcoma
We examined 24 primary OSA tumor specimens (six parosteal, 16 intramedullary and two extraskeletal) and four unrelated metastases for gene ampli®cation. CDK4 was ampli®ed in 6/6 parosteal and 1/2 extraskeletal OSA, but was not ampli®ed in 16 intramedullary tumors or four metastases (Tables 1  and 2 , Figure 1) . Each of the seven tumors with multiple copies of CDK4 also exhibited SAS amplification. In addition, two of 16 cases of intramedullary OSA exhibited ampli®cation and both involved only the SAS gene. In 4/5 parosteal tumors and 1/2 extraskeletal OSA, MDM2 was also found to be coampli®ed. There was no evidence of CDK2 (Figure 1 ), WNT1 or WNT10b gene ampli®cation in these tumors. A comparison of the two main types of OSA indicated that ampli®cation of CDK4, SAS and MDM2 occurred more frequently in parosteal tumors than in the more common intramedullary type of OSA (P=0.00001, P=0.0004, P=0.0008 respectively).
Expression of SAS, CDK4 and MDM2 in osteosarcomas
In the nine cases with gene ampli®cation, each ampli®ed gene exhibited a correspondingly elevated mRNA level. For each gene, the lowest mRNA level associated with gene ampli®cation was used as the cuto point for de®ning overexpression; these values were 3.4 for CDK4, 2.3 for SAS and 2.2 for MDM2 ( Figure  2 ). CDK4 and SAS were co-ampli®ed and overexpressed in all six parosteal tumors and in 1 extraskeletal OSA (Tables 1 and 2 ). MDM2 was also ampli®ed and overexpressed in the extraskeletal tumor and in 2/3 parosteal tumors for which RNA was available for analysis.
In the two intramedullary tumors with SAS ampli®cation the mRNA level was also elevated. In addition, four intramedullary tumors had increased SAS gene expression without ampli®cation (Tables 1  and 2 ). One of these intramedullary OSA overexpressed both CDK4 and SAS, while another had elevated SAS and MDM2. CDK2 had a consistently low mRNA level in all samples. Elevated mRNA levels of CDK4, SAS and MDM2 occurred more commonly 
Ampli®cation and overexpression in tumor progression specimens
For eight cases, we analysed at least two sequential tumor samples from each patient representing dierent surgical procedures including biopsy or resection of the primary tumor and metastasectomy. In addition four unrelated metastases were examined for ampli®cation (Table 2) . Ampli®cation did not appear to be associated with metastatic disease; gene ampli®cation was only observed in those metastatic lesions that also had ampli®cation in the primary specimen (Cases 1 and 7, Table 2 ). In each case of multiple specimens, neither the ampli®cation status nor the level of gene expression changed markedly with tumor progression.
Discussion
Gene ampli®cation and overexpression are generally thought to provide tumor cells with a selective growth Figure 1 Quantative PCR analysis of (22 ± 28 cycles) CDK4 and CDK2 DNA ampli®cation in human osteosarcomas. AS (asparagine synthetase) was used as an internal control and DNA copy number was normalized against placenta as described in Materials and methods. Samples with a twofold or greater increase in gene copy number relative to control unampli®ed DNA and indicated by * were considered to be ampli®ed Figure 2 Quantitative RT-PCR analysis of CDK4, SAS and MDM2 mRNA expression in human osteosarcomas. AS was used as an internal control. The relative expression values were normalized against the tumor cell line MCF-7. Values indicated by * were considered to be over-expressed, as described in results. Upper numbers indicate PCR cycles advantage. For example, ampli®cation of N-myc, c-myc and neu have been associated with an adverse prognosis in neuroblastoma, small cell lung carcinoma and breast cancer respectively (Seeger et al., 1985; Wong et al., 1986; Slamon et al., 1987) . Ampli®cation and overexpression of CDK4, SAS and MDM2 genes would also be expected to be associated with a more aggressive tumor phenotype. In fact, MDM2 amplification has been implicated in the progression of high grade OSA (Ladanyi et al., 1993) . It was therefore somewhat surprising to ®nd that parosteal OSA, which are of lower histologic grade and slower growing, were more likely to contain these molecular alterations than high grade intramedullary tumors. In addition, we did not observe ampli®cation or overexpression in lung metastases unless it was also present in the primary tumor (Table 2) .
Other studies support the suggestion that 12q13-15 ampli®cation does play a role in the pathogenesis of parosteal OSA. Using comparative genomic hybridization, two separate studies detected ampli®cation of this region in 2/3 and 7/7 cases of parosteal OSA, but not in any intramedullary tumors (Tarkkanen et al., 1995; Szymanska et al., 1996a) . In addition, Lonardo et al., (1997) identi®ed MDM2 ampli®cation more frequently in parosteal (2/8) compared to intramedullary OSA (3/ 67). Our results extend these observations by characterizing molecular alterations involving DNA ampli®cation and mRNA overexpression of additional speci®c genes within the 12q13-15 amplicon in parosteal OSA.
Involvement of 12q13-15 has been noted frequently in soft tissue sarcomas as well. Similar to our ®nding of 12q13-15 ampli®cation in the speci®c subset of parosteal OSA, this amplicon has been commonly identi®ed in retroperitoneal malignant ®brous histiocytoma and low grade liposarcomas (Smith et al., 1992; Forus et al., 1995; Szymanska et al., 1996b) . Interestingly, other soft tissue tumors of low grade or borderline malignancy have also been shown to have ampli®cation of 12q13-15 sequences (Orndal et al., 1992; Dal Cin et al., 1993; Suijkerbuijk et al., 1994) . This suggests molecular speci®city within certain histologic tumor types, as well as a possible predisposition for slow growing, lower grade tumors which commonly present with a large mass without metastases.
It is likely that in OSA the dierences reported for the frequency of ampli®cation of genes located at 12q13-15 are due to variations in the numbers of high grade intramedullary tumors and parosteal tumors included in the studies. For example, Oliner et al., (1992) reported ampli®cation of MDM2 in 3/11 (27%) cases of OSA; however, others have identi®ed MDM2 ampli®cation in only 4 ± 7% of cases (Nakayama et al., 1995; Miller et al., 1996; Lonardo et al., 1997) . We found SAS ampli®ed in 6/6 parosteal OSA and 2/16 intramedullary tumors. In comparison, Forus et al., (1993) reported SAS ampli®cation in only 2/17 (12%) tumors, however the types of OSA in that study were not presented. Furthermore, our results and others indicate that CDK4 may also be infrequently ampli®ed in intramedullary OSA (Forus et al., 1993; Maelandsmo et al., 1995) .
Recently, several other genes with oncogenic potential have been mapped to 12q13-15. CDK2 is similar to CDK4 in that it phosphorylates pRb at the G1/S transition leading to cell cycle progression, and could therefore provide tumor cells with a proliferative advantage (Akiyama et al., 1992; Tsai et al., 1993; Demetrick et al., 1994) . In contrast to CDK4, we did not observe CDK2 ampli®cation or overexpression in any OSA, including those samples with ampli®cation of other 12q13-15 genes. Recent studies have indicated that unlike CDK4, overexpression of CDK2 may not provide a bene®t to neoplastic cells; constitutive CDK2 expression did not rescue cells from either p53 or TGFb induced growth arrest (Ewen et al., 1993b; Latham et al., 1996) . Two other potential proto-oncogenes, WNT1 and WNT10b, were similarly not ampli®ed in any of the tumors (van't Veer et al., 1984; Bui et al., 1997) .
What drives the 12q13-15 amplicon?
SAS and CDK4 are tightly linked and frequently coampli®ed ; expression of these two genes has rarely been found to be discordant (Forus et al., 1993; Berner et al., 1996) . Our data support this since 6/6 parosteal tumors and 1 extraskeletal OSA exhibited ampli®cation and overexpression of both genes. Furthermore, the identification of a tumor with increased expression of both CDK4 and SAS, but without DNA ampli®cation, raises the possibility of a link between the transcriptional regulation of these two genes. Elevated gene expression usually occurs by transcriptional upregulation, with ampli®cation being a later event in association with very high levels of mRNA expression (e.g. Shen et al., 1986) . Therefore, increased expression of SAS and CDK4 may be a preliminary step toward 12q13-15 ampli®cation.
In every tumor with ampli®cation of genes on 12q, SAS was the only gene that was consistently ampli®ed. We identi®ed two intramedullary tumors which had ampli®cation and overexpression of SAS alone, as well as two other high grade tumors with elevated SAS mRNA as the only alteration, indicating that this critical region does not always include CDK4 or MDM2. MDM2 is located several megabases from SAS and CDK4 , and may be a separate target for ampli®cation (Nilbert et al., 1995; Berner et al., 1996; Reifenberger et al., 1996; Wolf et al., 1997) . However, we did not identify any tumor with MDM2 ampli®cation or overexpression unless SAS was also involved. These results suggest that SAS, or possibly a nearby gene (Su et al., 1994) likely plays an important role in parosteal OSA and may be the most critical gene in this amplicon.
Although the function of SAS is unknown, another member of the TM4SF gene family, KAI1, has been shown to suppress metastasis of prostate cancer cells injected into nude mice (Dong et al., 1995) without aecting the growth rate of the local tumor. More recently, KAI1 expression has been demonstrated to be downregulated during progression of human prostate cancer (Dong et al., 1996) . Decreased expression was also associated with poor survival in patients with prostate, pancreatic and non-small-cell lung cancers (Adachi et al., 1996; Guo et al., 1996; Dong et al., 1996) .
If SAS has a similar role to other members of the TM4SF family, its biological impact may depend on the pattern of involvement of other 12q13-15 genes in a particular tumor. For instance, overexpression of CDK4 and MDM2 can lead to deregulation of the cell cycle and may be important steps in tumor progression. In comparison, SAS may counteract these eects by preventing tumor metastasis. These competing functions may explain some of the clinical dierences between high grade intramedullary OSA and the generally lower grade parosteal tumors. Further studies on the dierences in molecular alterations in these two types of OSA may also shed light on the role of these as well as other putative growth control genes in tumorigenesis.
Materials and methods
Tumor samples
Human osteosarcoma samples were obtained from surgical specimens from 28 patients as previously described (NobleTopham et al., 1996) . Tumor DNA and total RNA were extracted using standard methods and quantitated with spectrophotometry (Sambrook et al., 1989) . DNA was also isolated from human placenta and total RNA from the human tumor cell line MCF-7 for use as internal controls throughout the study.
Quantitative reverse-transcriptase-PCR (RT ± PCR) for mRNA expression cDNA synthesis was performed using 200 ng total cellular RNA, 40 units MMLV reverse transcriptase, 50 mM Tris HCl (pH 7.5), 75 mM KCl, 3 mM MgCl 2 , 10 mM DTT, 2 mM dNTPs, 4 U RNasin and 40 ng random primer in an 8 ml reaction volume at 378C for 1 h (Noonan et al., 1990) . Following RT denaturation at 958C, PCR ampli®cation was carried out using 100 ng cDNA, MgCl 2 (0.5 mM for CDK4; 1.5 mM for SAS, MDM2, CDK2), 50 mM KCl, 10 mM Tris HCl (pH 7.5), 0.01% gelatin, 0.45 mM dNTPs, 1 unit Taq polymerase and either 1.0 mM (CDK2) or 1.9 mM of each primer in a ®nal volume of 12 ml. Asparagine synthetase (AS) was co-ampli®ed with the gene of interest in each reaction as an internal control. The reactions were denatured at 948C for 30 s, annealed for 30 s at 488C (608C for CDK2), and extended at 728C for 1 min in a Perkin-Elmer Cetus 4800 Thermocycler. RNA primers are as follows: CDK4RNA1 5'-CATGTA-GACCAGGACCTAAGG, CDK4RNA2 5'-GGAGGTCG-GTACCAGAGTG; SASRNA1 5'-CCCTGTATCAACAA-GATTATG, SASRNA2 5'-CAGGGCTTCGTCTGAA-TG; MDM2RNA1 5'-CAAGAACTCTCAGATGAAG-AT, MDM2RNA2 5'-AGGAACATCAAAGCCCTCT-TC; CDK2RNA1 5'-GAATTTCTGCACCAAGATCTC, CDK2RNA2 5'-AGGTTTAAGGTCTCGGTGGA; AS1 5'-ACATTGAAGCACTCCGCGAC, AS4 5'-CCTGAGG-TTGTTCTTCACAG. RNA speci®c primers were chosen to amplify a region containing at least one intron to prevent genomic DNA ampli®cation.
In order for PCR analysis to be quantitative, each sample was analysed over a range of cycles to ensure that the result could be obtained from the logarithmic phase of amplification, when the amount of product corresponds to the amount of the initial template (Noonan et al., 1990; Lee et al., 1996) . The products were separated on 12% polyacrylamide gels, stained with ethidium bromide and photographed for quantitative laser densitometry of each product band. The ratio of each gene to AS was normalized against MCF-7 to control for variations between specimens and PCR reactions.
Quantitative analysis of DNA ampli®cation MDM2 ampli®cation was assessed by Southern blot analysis as previously described (Chen et al. 1993; Cordon-Cardo et al., 1994) . Normalized values for MDM255 were considered to represent gene amplification. CDK2, WNT1 and WNT10b were each co-ampli®ed with AS by PCR under conditions similar to those listed above with the following changes: 608C annealing temperature, a 12 ml reaction volume containing 50 ng DNA, 1.1 mM MgCl 2 and 1 mM of each primer. CDK4 was also assayed with AS except in a 20 ml reaction volume with 1.6 mM MgCl 2 , 1.1 mM of each primer and in a PerkinElmer Cetus 9600 Thermocycler with denaturation at 948C for 15 s, annealing for 15 s at 608C and extension at 728C for 20 s. DNA primers are as follows: CDK4DNA1 5'-CTGAGAATGGCTACCTCTC, CDK4DNA2 5'-AG-CCACCTCACGAACTGTGC; CDK2DNA1 5'-TATC-TGTTCCAGCTGCTCCA, CDK2DNA2 5'-CATGGGTG-TAAGTACGAACAG; WNT1DNA1 5'-GCGCTTCC-TCATGAACCTTC, WNT1DNA2 5'-GTCTTCGTTCCA-AGCCTCCG; WNT10bDNA1 5'-TCTGCGTCCCCGTC-GCCTC, WNT10bDNA2 5'-GGCTGCCACAGCCATC-CAAC; AS1 (see above), AS5 5'-TGCAACTTTGCCA-TTTGGCT. Each sample was analysed over a range of cycles as described above for mRNA quantitation, however the ratio of each gene to AS was normalized against placental DNA. Tumors that exhibited a twofold or greater increase in the copy number relative to control unampli®ed DNA from placenta were considered to be ampli®ed.
